Two patients achieved control with cabergoline monotherapy, one with moderately elevated IGF-I (1.3 × ULN) and the other with a GH/PRL-secreting tumor, supporting prior data that these factors likely influence response to DA therapy. The gene discussed is PRL; the disease is neoplasm.